Significantly reduce wait times for life-saving medications. • YouBetcha

Current Status

Status: Not Started No concrete actions have been taken by the Carney government to reduce wait times for life-saving medications following Health Canada approval.

Background

During the 2025 federal election campaign, Mark Carney highlighted delays in public access to approved medications as a critical issue, noting that Canadian patients often wait longer than those in other G7 countries for life-saving drugs. He pledged to address this by streamlining processes and cutting red tape, emphasizing that reforms would not compromise safety standards while also supporting the research community. Fulfilling this promise would require regulatory changes to accelerate the timeline from Health Canada approval to public availability, potentially involving adjustments to reimbursement negotiations or provincial formularies, all while ensuring rigorous safety protocols remain intact. Prior governments, including Justin Trudeau's administration, had made some efforts to improve drug approval processes, but these did not directly tackle post-approval wait times for public access.

Evidence

As of March 26, 2026, no concrete actions by the Carney government specifically addressing reductions in wait times for life-saving medications post-Health Canada approval have been documented in the provided sources. In October 2025, Prime Minister Carney delivered remarks outlining broader economic plans ahead of Budget 2025, but these did not include tangible steps toward this promise[5][6]. Existing regulations under the Food and Drugs Act, such as those governing new drug submissions and notices of compliance, remain unchanged from prior administrations and do not reflect new initiatives under Carney[1][2][3]. Amendments to the Controlled Drugs and Substances Act in 2024, enacted under the previous government, focused on supervised consumption sites and did not pertain to medication wait times[4]. No legislative, regulatory, or policy changes initiated by the Carney government to cut red tape or shorten timelines for public access to approved drugs are evident.

Assessment

The Carney government has yet to deliver on its campaign promise to significantly reduce wait times for life-saving medications, with no verifiable progress toward cutting red tape or accelerating public access without compromising safety. While the promise aimed to position Canada more competitively among G7 peers by streamlining post-approval processes and supporting research, the absence of any regulatory reforms or policy implementations means patients continue to face the same delays that prompted the pledge. This lack of action underscores a gap between campaign rhetoric and governance, leaving the commitment unaddressed more than a year into Carney's term.

Current Status

Background

Evidence

Assessment

Sources